Richard Love - PAREXEL International Independent Director
Director
Mr. Richard L. Love is an Independent Director of Parexel International Corporationrationration. is a member of the Compensation Committee, the Nominating and Corporationrationrate Governance Committee and the Human Resources Committee. Since January 2007, Mr. Love has served as a partner of Translational Accelerator Venture Fund, an investment fund. Since October 2016, he has served as Interim President and Chief Executive Officer of CTI Biopharma, Inc., a biopharmaceutical company. From January 2003 to January 2007, he served as Chief Operating Officer of Translational Genomics Research Institute, a medical research organization, and from January 2002 to December 2004, he served as a director of ILEX Oncology, an oncology focused pharmaceutical company. From October 1994 to January 2002, Mr. Love served as President and Chief Executive Officer of ILEX Oncology. From 1991 to 1994, he served as Chief Operating Officer of the Cancer Therapy and Research Center, a cancer treatment center focused on the clinical evaluation of new agents. From 1983 to 1991, Mr. Love served as Chief Executive Officer of Triton Biosciences, Inc., a biotechnology company. Mr. Love currently serves as a director of CTI Biopharma, Inc., SyndevRx Inc., Applied Microarrays Inc., Cancer Prevention Pharmaceuticals, Inc. and CerRx Inc., and as a Manager on the Board of Managers of PMED Management LLC. since 2002.
| Age | 72 |
| Tenure | 22 years |
| Phone | 781 487-9900 |
| Web | http://www.parexel.com |
PAREXEL International Management Efficiency
The company has return on total asset (ROA) of 0.0471 % which means that it generated a profit of $0.0471 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.15 %, meaning that it created $0.15 on every $100 dollars invested by stockholders. PAREXEL International's management efficiency ratios could be used to measure how well PAREXEL International manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 671.5 M in liabilities with Debt to Equity (D/E) ratio of 105.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has a current ratio of 1.42, which is within standard range for the sector. Debt can assist PAREXEL International until it has trouble settling it off, either with new capital or with free cash flow. So, PAREXEL International's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PAREXEL International sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PAREXEL to invest in growth at high rates of return. When we think about PAREXEL International's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jemaluddin Kassum | Barrick Gold Corp | 68 | |
| Jeanine Lioko | Barrick Gold Corp | 52 | |
| Michelle Wilson | 57 | ||
| Robert Prichard | Barrick Gold Corp | 68 | |
| Michael Evans | Barrick Gold Corp | 60 | |
| Ernie Thrasher | Barrick Gold Corp | 61 | |
| Susan Ellerbusch | Summit Materials | 53 | |
| Andrea Wishom | 50 | ||
| Gustavo Cisneros | Barrick Gold Corp | 74 | |
| Philip Asherman | Arrow Electronics | 67 | |
| Graham Clow | Barrick Gold Corp | 66 | |
| Laurel Krzeminski | Arrow Electronics | 66 | |
| Gail Hamilton | Arrow Electronics | 71 | |
| Andrew Kerin | Arrow Electronics | 57 | |
| Julia Kahr | Summit Materials | 37 | |
| Safiatou BaNDaw | Barrick Gold Corp | 64 | |
| Barry Perry | Arrow Electronics | 74 | |
| Steven Shapiro | Barrick Gold Corp | 65 | |
| Brett Harvey | Barrick Gold Corp | 67 | |
| Fredric Reynolds | 70 | ||
| Olivia Kirtley | Barrick Gold Corp | 66 | |
Management Performance
| Return On Equity | 0.15 | |||
| Return On Asset | 0.0471 |
PAREXEL International Leadership Team
Elected by the shareholders, the PAREXEL International's board of directors comprises two types of representatives: PAREXEL International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PAREXEL. The board's role is to monitor PAREXEL International's management team and ensure that shareholders' interests are well served. PAREXEL International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PAREXEL International's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michelle Graham, Chief Human Resource Officer, Senior Vice President | ||
| Ulf Schneider, Chief Administrative Officer, Senior Vice President | ||
| Thomas Senderovitz, Senior Vice President - Clinical Research Services | ||
| Dana Callow, Presiding Independent Director | ||
| Emma Reeve, Interim CFO, Corporate Vice President Controller | ||
| Josef Rickenbach, Founder, Chairman and CEO | ||
| Patrick Fortune, Independent Director | ||
| Eduard Holdener, Independent Director | ||
| Simon Harford, CFO, Senior Vice President | ||
| Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access | ||
| Gadi Saarony, Senior Vice President - Clinical Research Services | ||
| Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center | ||
| Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting | ||
| Xavier Flinois, President - Perceptive Informatics | ||
| Douglas Batt, Sr. VP, General Counsel and Secretary | ||
| Sybrand Pretorius, Senior Vice President Chief Scientific Officer | ||
| Maykin Ho, Director | ||
| Richard Love, Independent Director | ||
| Ronald Aldridge, Sr. Director, Investor Relations | ||
| Mark Goldberg, President COO | ||
| Roland Andersson, Senior Vice President - Clinical Research Services | ||
| Christopher Lindop, Independent Director | ||
| Ingo Bank, CFO and Sr. VP | ||
| David Godwin, Senior Vice President-Global Business |
PAREXEL Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PAREXEL International a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | |||
| Return On Asset | 0.0471 | |||
| Profit Margin | 0.04 % | |||
| Operating Margin | 11.04 % | |||
| Current Valuation | 4.87 B | |||
| Shares Outstanding | 51.12 M | |||
| Shares Owned By Insiders | 2.00 % | |||
| Shares Owned By Institutions | 90.14 % | |||
| Number Of Shares Shorted | 506.64 K | |||
| Price To Earning | 42.76 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PAREXEL International using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in PAREXEL Stock
If you are still planning to invest in PAREXEL International check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PAREXEL International's history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |